Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 6;13(2):293–300. doi: 10.1111/cts.12709

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Overall survival in patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT) in patients receiving busulfan‐based myeloablative conditioning. (a) Human leukocyte antigen (HLA)‐A, HLA‐B, and HLA‐DR matched unrelated donor (MUD) compared with mismatched (MM) donors and matched related donor (MRD). (b) Late disease phases (> CR1/CP1) compared with early disease phase. (c) Male patients with immunized female donors compared female patients with male donors or others. ImmFtoM, immunized female donor to male recipient; FtoM, female donor to male recipient; ns, not significant.